Skip to main content
Caplight Logo









IM Therapeutics

IM Therapeutics

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://aurimitx.com/

Last Round

Series A

Oct 9, 2019

Total Funding Raised

$10.23M

Company Overview

IM Therapeutics is a clinical-stage biopharmaceutical company that develops personalized oral therapies for autoimmune diseases by targeting human leukocyte antigen (HLA) gene variants.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision medicinesmall-molecule therapeuticsautoimmune diseasedrug discoveryhuman leukocyte antigenHLAcomputational drug discoveryin-silico drug designbiotechtype 1 diabetesceliac diseaseclinical-stage biotechrational drug designdrug pipelinepharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

IM Therapeutics Comparables

Compare IM Therapeutics with similar companies based on industry and business-model similarity.

IM Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Phaim Pharma
84%
Imcyse
81%
Anokion
74%

IM Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 9, 2019
GrantNov 14, 2018

IM Therapeutics Investors

Notable investors and investment history

IM Therapeutics investors
InvestorRounds
NIH RADxGrant
Morningside VenturesSeries A
JDRFSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 9, 2019

    $10M round led by Morningside Ventures and JDRF.

  • Nov 14, 2018

    $225K grant received from Americas Seed Fund and NIH RADx.

IM Therapeutics Filings

Explore SEC and related filing metadata, where available.

IM Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about IM Therapeutics's valuation, stock price, and market status.

Is IM Therapeutics a public or private company?

IM Therapeutics is a private company.

What is the current stock price of IM Therapeutics?

IM Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is IM Therapeutics worth (valuation)?

Valuation information for IM Therapeutics is not publicly available.

Can I buy IM Therapeutics stock?

IM Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was IM Therapeutics's last funding round?

IM Therapeutics's most recent funding round was Series A on October 9, 2019.

Who are the main investors in IM Therapeutics?

Key investors in IM Therapeutics include JDRF.

Will IM Therapeutics IPO soon?

No public IPO plans have been announced for IM Therapeutics.

How can I track IM Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor IM Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range2
Year Founded2015
Last FundingOct 9, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?